KR100954625B1 - 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물 - Google Patents

선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물 Download PDF

Info

Publication number
KR100954625B1
KR100954625B1 KR1020047006101A KR20047006101A KR100954625B1 KR 100954625 B1 KR100954625 B1 KR 100954625B1 KR 1020047006101 A KR1020047006101 A KR 1020047006101A KR 20047006101 A KR20047006101 A KR 20047006101A KR 100954625 B1 KR100954625 B1 KR 100954625B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
inhibitor
fluoro
methyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047006101A
Other languages
English (en)
Korean (ko)
Other versions
KR20040048992A (ko
Inventor
잉-난 판 첸
피터 라쏘타
알렉산더 웰리스 우드
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20040048992A publication Critical patent/KR20040048992A/ko
Application granted granted Critical
Publication of KR100954625B1 publication Critical patent/KR100954625B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020047006101A 2001-10-25 2002-10-24 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물 Expired - Fee Related KR100954625B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US60/344,734 2001-10-25
US60/344,735 2001-10-25
US33603301P 2001-11-15 2001-11-15
US60/336,033 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (2)

Publication Number Publication Date
KR20040048992A KR20040048992A (ko) 2004-06-10
KR100954625B1 true KR100954625B1 (ko) 2010-04-27

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047006101A Expired - Fee Related KR100954625B1 (ko) 2001-10-25 2002-10-24 선택적 사이클로옥시게나제-2 억제제를 포함하는 조합물

Country Status (22)

Country Link
US (2) US20050043409A1 (enExample)
EP (1) EP1441714B1 (enExample)
JP (1) JP2005506366A (enExample)
KR (1) KR100954625B1 (enExample)
CN (1) CN100506224C (enExample)
AT (1) ATE381930T1 (enExample)
AU (2) AU2006252156A1 (enExample)
BR (1) BR0213486A (enExample)
CA (1) CA2464309C (enExample)
CY (1) CY1108045T1 (enExample)
DE (1) DE60224299T2 (enExample)
DK (1) DK1441714T3 (enExample)
ES (1) ES2295428T3 (enExample)
HU (1) HUP0600235A3 (enExample)
IL (1) IL161462A0 (enExample)
MX (1) MXPA04003878A (enExample)
NZ (2) NZ532418A (enExample)
PL (1) PL369305A1 (enExample)
PT (1) PT1441714E (enExample)
RU (1) RU2333754C2 (enExample)
SI (1) SI1441714T1 (enExample)
WO (1) WO2003035047A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
WO2005021554A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
MXPA06003164A (es) * 2003-09-23 2006-06-05 Novartis Ag Combinaciones de un inhibidor del receptor de vegf con otros agentes terapeuticos.
JP2007505938A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
CA2551508C (en) 2003-12-23 2011-08-09 Pfizer Inc. Novel quinoline derivatives
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN103917236A (zh) 2011-11-11 2014-07-09 诺华股份有限公司 治疗增生性疾病的方法
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011605A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
WO2001040216A1 (en) * 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
WO2001060365A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100558356C (zh) * 1996-10-15 2009-11-11 G.D.瑟尔公司 应用环加氧酶-2抑制剂治疗和预防肿瘤形成的方法
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
CA2356462A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
IL147913A0 (en) * 1999-08-12 2002-08-14 American Cyanamid Co Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259236A4 (en) * 2000-02-25 2004-11-03 Merck & Co Inc Tyrosine kinase inhibitors
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011605A1 (en) * 1997-08-28 1999-03-11 Novartis Ag Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
WO2001040216A1 (en) * 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
WO2001060365A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents

Also Published As

Publication number Publication date
CA2464309C (en) 2012-01-03
AU2010200433A1 (en) 2010-02-25
PL369305A1 (en) 2005-04-18
CN100506224C (zh) 2009-07-01
US20050043409A1 (en) 2005-02-24
WO2003035047A2 (en) 2003-05-01
DK1441714T3 (da) 2008-03-31
BR0213486A (pt) 2005-05-10
NZ552335A (en) 2008-11-28
ATE381930T1 (de) 2008-01-15
EP1441714A2 (en) 2004-08-04
KR20040048992A (ko) 2004-06-10
SI1441714T1 (sl) 2008-06-30
JP2005506366A (ja) 2005-03-03
EP1441714B1 (en) 2007-12-26
WO2003035047A3 (en) 2003-10-23
HK1068261A1 (en) 2005-04-29
HUP0600235A3 (en) 2008-04-28
RU2333754C2 (ru) 2008-09-20
DE60224299D1 (de) 2008-02-07
IL161462A0 (en) 2004-09-27
RU2004116069A (ru) 2005-06-10
ES2295428T3 (es) 2008-04-16
AU2006252156A1 (en) 2007-01-18
PT1441714E (pt) 2008-03-10
HUP0600235A2 (en) 2007-02-28
MXPA04003878A (es) 2004-07-08
NZ532418A (en) 2007-02-23
CN1575168A (zh) 2005-02-02
CY1108045T1 (el) 2013-09-04
US20110046190A1 (en) 2011-02-24
CA2464309A1 (en) 2003-05-01
DE60224299T2 (de) 2008-12-11

Similar Documents

Publication Publication Date Title
US20110046190A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
US9421208B2 (en) Methods for the treatment of solid tumors
US20060270665A1 (en) Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
US10398789B2 (en) Methods, compositions and kits for providing a therapeutic treatment
US7723339B2 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
MX2008016125A (es) Compuestos organicos.
CN114246864B (zh) Csf1r激酶抑制剂及其用途
AU2007247112B2 (en) Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
JP2025530742A (ja) エストロゲン受容体分解物質の投与計画
AU2002351784A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
ZA200402939B (en) Combinations comprising a selective cyclooxygenase-2 inhibitor.
WO2025229051A1 (en) Use of atr inhibitors in combination with antiandrogen agent
WO2025214358A1 (zh) 用于治疗胰腺癌的药物及其用途
WO2025181153A1 (en) Use of atr inhibitors in combination with pi3k alpha inhibitors
HK1068261B (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
CZ20032277A3 (cs) Kombinace inhibitoru přenosu signálu a derivátu epothilonu k léčení proliferativních onemocnění

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20130321

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140417

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140417

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000